Printed from https://ideas.repec.org/s/spr/eujhec3.html
Content
November 2021, Volume 22, Issue 8
- 1239-1251 On the correlation between outcome indicators and the structure and process indicators used to proxy them in public health care reporting
by Benjamin H. Salampessy & France R. M. Portrait & Eric Hijden & Ab Klink & Xander Koolman - 1253-1273 Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges
by Carlo Federici & Vivian Reckers-Droog & Oriana Ciani & Florian Dams & Bogdan Grigore & Zoltán Kaló & Sándor Kovács & Kosta Shatrov & Werner Brouwer & Michael Drummond - 1275-1288 Health state utility values by cancer stage: a systematic literature review
by Mir-Masoud Pourrahmat & Ashley Kim & Anuraag R. Kansal & Marg Hux & Divya Pushkarna & Mir Sohail Fazeli & Karen C. Chung - 1289-1299 Business cycle and mortality in Spain
by María Cervini-Plá & Judit Vall-Castelló - 1301-1309 Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms
by Koonal K. Shah & Bryan Bennett & Andrew Lenny & Louise Longworth & John E. Brazier & Mark Oppe & A. Simon Pickard & James W. Shaw - 1311-1344 Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies
by Nikolai Mühlberger & Gaby Sroczynski & Artemisa Gogollari & Beate Jahn & Nora Pashayan & Ewout Steyerberg & Martin Widschwendter & Uwe Siebert
September 2021, Volume 22, Issue 7
- 1001-1004 COVID-19: not the time for health economists? A plea for more proactive health economic involvement
by J.-Matthias Graf von der Schulenburg - 1005-1016 How the COVID-19 pandemic can distort risk adjustment of health plan payment
by Richard C. Kleef & Mieke Reuser - 1017-1024 The impact of COVID-19 pandemic on insurance demand: the case of China
by Xianhang Qian - 1025-1038 Can the Covid19 pandemic affect the achievement of the ‘Zero Hunger’ goal? Some preliminary reflections
by Donatella Saccone - 1039-1052 Evolution of health care utilization and expenditure during the year before death in 2015 among people with cancer: French snds-based cohort study
by Audrey Tanguy-Melac & Dorian Verboux & Laurence Pestel & Anne Fagot-Campagna & Philippe Tuppin & Christelle Gastaldi-Ménager - 1053-1065 Economics of mental well-being: a prospective study estimating associated health care costs and sickness benefit transfers in Denmark
by Ziggi Ivan Santini & Hannah Becher & Maja Bæksgaard Jørgensen & Michael Davidsen & Line Nielsen & Carsten Hinrichsen & Katrine Rich Madsen & Charlotte Meilstrup & Ai Koyanagi & Sarah Stewart-Brown & David McDaid & Vibeke Koushede - 1067-1081 What is the best approach to adopt for identifying the domains for a new measure of health, social care and carer-related quality of life to measure quality-adjusted life years? Application to the development of the EQ-HWB?
by Tessa Peasgood & Clara Mukuria & Jill Carlton & Janice Connell & Nancy Devlin & Karen Jones & Rosemary Lovett & Bhash Naidoo & Stacey Rand & Juan Carlos Rejon-Parrilla & Donna Rowen & Aki Tsuchiya & John Brazier - 1083-1093 Testing measurement properties of two EQ-5D youth versions and KIDSCREEN-10 in China
by Wang Pei & Sun Yue & Yang Zhi-Hao & Zhang Ruo-Yu & Wu Bin & Luo Nan - 1095-1101 Obesity Kuznets curve and the reality of eco-income ellipsoids (EIE)
by Andrew Adewale Alola & Festus Victor Bekun - 1103-1113 Patient-caregiver agreement and test–retest reliability of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients with haematological malignancies
by Wenjing Zhou & Anle Shen & Zhihao Yang & Pei Wang & Bin Wu & Michael Herdman & Nan Luo - 1115-1128 Assessing the consequences of quarantines during a pandemic
by Rikard Forslid & Mathias Herzing - 1129-1139 The relationship between renewable energy use and health expenditures in EU countries
by Mahmut Unsal Sasmaz & Aysun Karamıklı & Ulas Akkucuk
August 2021, Volume 22, Issue 6
- 851-854 Something borrowed, something new: measuring hospital performance in the context of value based health care
by Peter Lindgren & Rikard Althin - 855-864 Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting
by Arnaud Bayle & N. Droin & B. Besse & Z. Zou & Y. Boursin & S. Rissel & E. Solary & L. Lacroix & E. Rouleau & I. Borget & J. Bonastre - 865-872 Comparison of self-reported and public registered absenteeism among people on long-term sick leave due to musculoskeletal disorders: criterion validity of the iMTA Productivity Cost Questionnaire
by Rikke Munk Killingmo & Anne Therese Tveter & Milada C. Småstuen & Kjersti Storheim & Margreth Grotle - 873-885 Health-economic evaluation of collaborative orthogeriatric care for patients with a hip fracture in Germany: a retrospective cohort study using health and long-term care insurance claims data
by Claudia Schulz & Gisela Büchele & Raphael S. Peter & Dietrich Rothenbacher & Christian Brettschneider & Ulrich C. Liener & Clemens Becker & Kilian Rapp & Hans-Helmut König - 887-903 Mass media coverage and vaccination uptake: evidence from the demand for meningococcal vaccinations in Hungary
by Anikó Bíró & Ágnes Szabó-Morvai - 905-915 The causal impact of sugar taxes on soft drink sales: evidence from France and Hungary
by Christoph F. Kurz & Adriana N. König - 917-929 Regional medical practice variation in high-cost healthcare services
by Michael Berger & Thomas Czypionka - 931-949 Using fees to reduce bed-blocking: a game between hospitals and long-term care providers
by Snorre Kverndokk & Hans Olav Melberg - 951-960 Different levels of care for follow-up of adults with congenital heart disease: a cost analysis scrutinizing the impact on medical costs, hospitalizations, and emergency department visits
by Ruben Willems & Fouke Ombelet & Eva Goossens & Katya De Groote & Werner Budts & Stéphane Moniotte & Michèle de Hosson & Liesbet Van Bulck & Ariane Marelli & Philip Moons & Julie De Backer & Lieven Annemans - 961-975 Economic evidence with respect to cost-effectiveness of the transitional care model among geriatric patients discharged from hospital to home: a systematic review
by Kristina Kast & Carl-Philipp Wachter & Oliver Schöffski & Martina Rimmele - 977-989 Home sweet home: GPs’ response to an increase in the fee size for home visits
by Jamie O’Halloran & Anne Sophie Oxholm & Line Bjørnskov Pedersen & Dorte Gyrd-Hansen - 991-999 Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands
by Marije E. Hagendijk & Simon Schans & Cornelis Boersma & Maarten J. Postma & Simon Pol
July 2021, Volume 22, Issue 5
- 661-667 The “red herring” after 20 years: ageing and health care expenditures
by Friedrich Breyer & Normann Lorenz - 669-677 A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
by Michaela Carla Barbier & Esther Pardo & Cédric Michael Panje & Oliver Gautschi & Judith Eva Lupatsch - 679-697 Trust me; I know what I am doing investigating the effect of choice list elicitation and domain-relevant training on preference reversals in decision making for others
by Sebastian Neumann-Böhme & Stefan A. Lipman & Werner B. F. Brouwer & Arthur E. Attema - 699-709 How Managed Entry Agreements can improve allocation in the public health system: a mechanism design approach
by Shuli Brammli-Greenberg & Ira Yaari & Elad Daniels & Ariella Adijes-Toren - 711-721 Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses
by Mark Oppe & Daniela Ortín-Sulbarán & Carlos Vila Silván & Anabel Estévez-Carrillo & Juan M. Ramos-Goñi - 723-733 Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists
by Michael J. Zoratti & A. Simon Pickard & Peep F. M. Stalmeier & Daniel Ollendorf & Andrew Lloyd & Kelvin K W Chan & Don Husereau & John E. Brazier & Murray Krahn & Mitchell Levine & Lehana Thabane & Feng Xie - 735-747 Mapping PedsQL™ Generic Core Scales to EQ-5D-3L utility scores in transfusion-dependent thalassemia patients
by Asrul Akmal Shafie & Irwinder Kaur Chhabra & Jacqueline Hui Yi Wong & Noor Syahireen Mohammed - 749-771 Are long-term care jobs harmful? Evidence from Germany
by Thomas Rapp & Jérôme Ronchetti & Jonathan Sicsic - 773-788 Bayesian modeling of health state preferences: could borrowing strength from existing countries’ valuations produce better estimates
by Samer A. Kharroubi & Yara Beyh - 789-810 Has the development of cancer biomarkers to guide treatment improved health outcomes?
by Ana Beatriz D′Avó Luís & Mikyung Kelly Seo - 811-831 Risky business, healthy lives: how risk perception, risk preferences and information influence consumer’s risky health choices
by Jean Spinks & Son Nghiem & Joshua Byrnes - 833-846 The impact of nurse staffing levels on nursing-sensitive patient outcomes: a multilevel regression approach
by Karina Dietermann & Vera Winter & Udo Schneider & Jonas Schreyögg - 847-847 Correction to: A general framework for classifying costing methods for economic evaluation of health care
by Zuzana Špacírová & David Epstein & Leticia García-Mochón & Joan Rovira & Antonio Olry de Labry Lima & Jaime Espín - 849-849 Correction to: How relevant are social costs in economic evaluations? The case of Alzheimer’s disease
by L. M. Peña-Longobardo & B. Rodríguez-Sánchez & J. Oliva-Moreno & I. Aranda-Reneo & J. López-Bastida
June 2021, Volume 22, Issue 4
- 499-504 Awaiting the “catharsis”
by John Yfantopoulos - 505-518 Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018
by Alice Morgan & Sally Hartmanis & Emmanuel Tsochatzis & Philip N. Newsome & Stephen D. Ryder & Rachel Elliott & Lefteris Floros & Richard Hall & Victoria Higgins & George Stanley & Sandrine Cure & Sharad Vasudevan & Lynne Pezzullo - 519-529 Beyond price: the effects of non-financial barriers on access to drugs and health outcomes
by Lucia Leporatti & Rosella Levaggi & Marcello Montefiori - 531-545 Adjusted productivity costs of stroke by human capital and friction cost methods: a Northern Finland Birth Cohort 1966 study
by Ina Rissanen & Leena Ala-Mursula & Iiro Nerg & Marko Korhonen - 547-557 Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia
by Richard Huan Xu & Dong Dong & Nan Luo & Eliza Lai-Yi Wong & Yushan Wu & Siyue Yu & Renchi Yang & Junshuai Liu & Huiqin Yuan & Shuyang Zhang - 559-569 The economics of alternative payment models for pharmaceuticals
by Jakub P. Hlávka & Jeffrey C. Yu & Dana P. Goldman & Darius N. Lakdawalla - 571-584 Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations
by Kamolpat Chaiyakittisopon & Oraluck Pattanaprateep & Narisa Ruenroengbun & Tunlanut Sapankaew & Atiporn Ingsathit & Gareth J. Mckay & John Attia & Ammarin Thakkinstian - 585-604 Economic analysis of open versus laparoscopic versus robotic hepatectomy: a systematic review and meta-analysis
by Ioannis A. Ziogas & Alexandros P. Evangeliou & Konstantinos S. Mylonas & Dimitrios I. Athanasiadis & Panagiotis Cherouveim & David A. Geller & Richard D. Schulick & Sophoclis P. Alexopoulos & Georgios Tsoulfas - 605-620 The cost of chemotherapy administration: a systematic review and meta-analysis
by Gursharan K. Sohi & Jordan Levy & Victoria Delibasic & Laura E. Davis & Alyson L. Mahar & Elmira Amirazodi & Craig C. Earle & Julie Hallet & Ahmed Hammad & Rajan Shah & Nicole Mittmann & Natalie G. Coburn - 621-628 Comparison of the three-level and the five-level versions of the EQ-5D
by Anne Simone Juhl Christiansen & Marie Louise Sletskov Møller & Christian Kronborg & Ketil Jørgen Haugan & Lars Køber & Søren Højberg & Axel Brandes & Claus Graff & Søren Zöga Diederichsen & Jonas Bille Nielsen & Derk Krieger & Anders Gaarsdal Holst & Jesper Hastrup Svendsen - 629-642 Are regions equal in adversity? A spatial analysis of spread and dynamics of COVID-19 in Europe
by Mounir Amdaoud & Giuseppe Arcuri & Nadine Levratto - 643-658 Rising unemployment reduces the demand for healthcare services among people with cardiovascular disease: an Australian cohort study
by Clifford Afoakwah & Son Nghiem & Paul Scuffham & Joshua Byrnes - 659-660 Correction to: Health-economic evaluation of home telemonitoring for COPD in Germany: evidence from a large population-based cohort
by Dmitrij Achelrod & Jonas Schreyögg & Tom Stargardt
April 2021, Volume 22, Issue 3
- 351-355 Accountability for an unhealthy lifestyle
by Daniel M. Campagne - 357-363 Discounting in economic evaluation of healthcare interventions: what about the risk term?
by Lars Hultkrantz - 365-380 German tariffs for the ICECAP-Supportive Care Measure (ICECAP-SCM) for use in economic evaluations at the end of life
by Judith Dams & Elisabeth Huynh & Steffi Riedel-Heller & Margrit Löbner & Christian Brettschneider & Hans-Helmut König - 381-392 The effect of alcohol tax changes on retail prices: how do on-trade alcohol retailers pass through tax changes to consumers?
by Luke B. Wilson & Robert Pryce & Colin Angus & Rosemary Hiscock & Alan Brennan & Duncan Gillespie - 393-403 Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer
by Eduard Vrdoljak & Mario Sekerija & Stjepko Plestina & Ingrid Belac Lovasic & Vera Katalinic Jankovic & Livio Garattini & Ana Bobinac & Luka Voncina - 405-423 Health measures and long-term care use in the European frail population
by Quitterie Roquebert & Jonathan Sicsic & Thomas Rapp - 425-443 Personalized diabetes management: what do patients with diabetes mellitus prefer? A discrete choice experiment
by Axel C. Mühlbacher & Andrew Sadler & Christin Juhnke - 445-454 Cost-effectiveness of the latent tuberculosis screening program for migrants in Stockholm Region
by Jad Shedrawy & Charlotte Deogan & Joanna Nederby Öhd & Maria-Pia Hergens & Judith Bruchfeld & Jerker Jonsson & Andrew Siroka & Knut Lönnroth - 455-462 COVID-19 and income inequality in OECD countries
by John Wildman - 463-471 Does the universal medical insurance system reduce catastrophic health expenditure among middle-aged and elderly households in China? A longitudinal analysis
by Yue Zhou & Haishaerjiang Wushouer & Daniel Vuillermin & Xiaodong Guan & Luwen Shi - 473-483 The impact of social health insurance on rural populations
by Colin Green & Bruce Hollingsworth & Miaoqing Yang - 485-497 Economic and social cost of epilepsy in Poland: 5-year analysis
by Joanna Jędrzejczak & Beata Majkowska-Zwolińska & Anna Chudzicka-Bator & Iwona Żerda & Magdalena Władysiuk & Brian Godman
March 2021, Volume 22, Issue 2
- 183-186 More room for telemedicine after COVID-19: lessons for primary care?
by Livio Garattini & Marco Badinella Martini & Michele Zanetti - 187-193 Revisiting the Swedish alcohol stasis after changes in travelers’ allowances in 2004: petrol prices provide a piece of the puzzle
by Stefan K. Lhachimi - 195-221 Factors related to the change in Swiss inpatient costs by disease: a 6-factor decomposition
by Michael Stucki - 223-228 Sex differences in cigarette brand purchases among adult smokers: results from the DePICT national repeated survey of French adults (2016–2017)
by Fabienne El-Khoury Lesueur & Hugo Torregrossa & Ramchandar Gomajee & Camille Bolze & Maria Melchior - 229-242 Does NICE influence the adoption and uptake of generics in the UK?
by Victoria Serra-Sastre & Simona Bianchi & Jorge Mestre-Ferrandiz & Phill O’Neill - 243-254 Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events
by Fränce Hardtstock & Zeki Kocaata & Thomas Wilke & Axel Dittmar & Marco Ghiani & Vasily Belozeroff & David J. Harrison & Ulf Maywald & Hans Tesch - 255-266 Employer survey to estimate the productivity friction period
by Kathleen Manipis & Stephen Goodall & Paul Hanly & Rosalie Viney & Alison Pearce - 267-279 Efficiency and productivity of health systems in prevention and control of non-communicable diseases in China, 2008–2015
by Peipei Chai & Quan Wan & Yohannes Kinfu - 281-309 Voluntary private health insurance, health-related behaviours and health outcomes: evidence from Russia
by Andrey Aistov & Ekaterina Aleksandrova & Christopher J. Gerry - 311-327 COVID-19 and the role of inequality in French regional departments
by Victor Ginsburgh & Glenn Magerman & Ilaria Natali - 329-339 Does socioeconomic status affect hospital utilization and health outcomes of chronic disease patients?
by Jongsay Yong & Ou Yang - 341-350 Mapping MacNew Heart Disease Quality of Life Questionnaire onto country-specific EQ-5D-5L utility scores: a comparison of traditional regression models with a machine learning technique
by Lan Gao & Wei Luo & Utsana Tonmukayakul & Marj Moodie & Gang Chen
February 2021, Volume 22, Issue 1
- 1-4 Do European pharmacists really have to trespass on medicine?
by Livio Garattini & Anna Padula & Nicholas Freemantle - 5-16 ‘Relative Consent’ or ‘Presumed Consent’? Organ donation attitudes and behaviour
by Joan Costa-Font & Caroline Rudisill & Maximilian Salcher-Konrad - 17-33 Increasing respondent engagement in composite time trade-off tasks by imposing three minimum trade-offs to improve data quality
by Ruixuan Jiang & Thomas Kohlmann & Todd A. Lee & Axel Mühlbacher & James Shaw & Surrey Walton & A. Simon Pickard - 35-50 Very high and low residual spenders in private health insurance markets: Germany, The Netherlands and the U.S. Marketplaces
by Thomas G. McGuire & Sonja Schillo & Richard C. Kleef - 51-73 A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England
by Nasuh C. Buyukkaramikli & Peter Wigfield & Men Thi Hoang - 75-88 Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands
by Job F. H. Eijsink & Mohamed N. M. T. Al Khayat & Cornelis Boersma & Peter G. J. Horst & Jan C. Wilschut & Maarten J. Postma - 89-100 A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme
by Martin Connock & Peter Auguste & Xavier Armoiry - 101-114 Do discontinuities in marginal reimbursement affect inpatient psychiatric care in Germany?
by Clara Pott & Tom Stargardt & Udo Schneider & Simon Frey - 115-139 Accreditation as a quality-improving policy tool: family planning, maternal health, and child health in Egypt
by Amira El-Shal & Patricia Cubi-Molla & Mireia Jofre-Bonet - 141-153 Multi-layer health insurance coverage, medical services use and health in a Universal National Health System, the case of Portugal
by Aida Isabel Tavares & Inês Marques - 155-168 The impact of taxing sugar-sweetened beverages on cola purchasing in Catalonia: an approach to causal inference with time series cross-sectional data
by Lluc Puig-Codina & Jaime Pinilla & Jaume Puig-Junoy - 169-180 Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
by Frida Schain & Nurgul Batyrbekova & Johan Liwing & Simona Baculea & Thomas Webb & Mats Remberger & Jonas Mattsson - 181-181 Correction to: Healthcare expenditure and carbon footprint in the USA: evidence from hidden cointegration approach
by Murat Gündüz
December 2020, Volume 21, Issue 9
- 1273-1277 Efficiency ratio and rocketing drug prices: old concerns and new possibilities
by Stefano Capri & Fernando Antonanzas - 1279-1293 The impact of the diabetes management incentive on diabetes-related services: evidence from Ontario, Canada
by Thaksha Thavam & Rose Anne Devlin & Amardeep Thind & Gregory S. Zaric & Sisira Sarma - 1295-1315 General practitioners’ income and activity: the impact of multi-professional group practice in France
by Matthieu Cassou & Julien Mousquès & Carine Franc - 1317-1327 Modelling the cost-effectiveness of person-centred care for patients with acute coronary syndrome
by Laura Pirhonen & Hanna Gyllensten & Andreas Fors & Kristian Bolin - 1329-1350 Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature
by Klas Kellerborg & Werner Brouwer & Pieter Baal - 1351-1361 Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany
by Edin Basic & Mathias Kappel & Arpit Misra & Leopold Sellner & Boris A. Ratsch & Dennis A. Ostwald - 1363-1373 Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas
by Richard Huan Xu & Eliza Lai Yi Wong & Jun Jin & Ying Dou & Dong Dong - 1375-1389 No gain in pain: psychological well-being, participation, and wages in the BHPS
by Elena Lagomarsino & Alessandro Spiganti - 1391-1398 How French general practitioners respond to declining medical density: a study on prescription practices, with an insight into opioids use
by Julien Silhol & Bruno Ventelou & Anna Zaytseva - 1399-1410 Timing matters: worker absenteeism in a weekly backward rotating shift model
by Bernd Frick & Robert Simmons & Friedrich Stein - 1411-1420 Multiplicative modelling of EQ-5D-3L TTO and VAS values
by Asrul Akmal Shafie & Annushiah Vasan Thakumar - 1421-1437 HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies
by Doug Coyle & Isabelle Durand-Zaleski & Jasmine Farrington & Louis Garrison & Johann-Matthias Graf von der Schulenburg & Wolfgang Greiner & Louise Longworth & Aurélie Meunier & Anne-Sophie Moutié & Stephen Palmer & Zack Pemberton-Whiteley & Mark Ratcliffe & Jie Shen & Doug Sproule & Kun Zhao & Koonal Shah
November 2020, Volume 21, Issue 8
- 1117-1120 Should health technology assessment be more patient centric? If so, how?
by Michael Drummond & Aleksandra Torbica & Rosanna Tarricone - 1121-1129 Using machine learning to assess the predictive potential of standardized nursing data for home healthcare case-mix classification
by Maud H. Korte & Gertjan S. Verhoeven & Arianne M. J. Elissen & Silke F. Metzelthin & Dirk Ruwaard & Misja C. Mikkers - 1131-1147 The effect of long-term care public benefits and insurance on informal care from outside the household: empirical evidence from Italy and Spain
by Christophe Courbage & Guillem Montoliu-Montes & Joël Wagner - 1149-1168 Investigating the geographic disparity in quality of care: the case of hospital readmission after acute myocardial infarction in Italy
by Yuxi Wang & Simone Ghislandi & Aleksandra Torbica - 1169-1178 EQ-5D-5L Bulgarian population norms
by Marta Encheva & Slaveyko Djambazov & Toni Vekov & Dominik Golicki - 1179-1196 Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy
by J. Pöhlmann & K. Norrbacka & K. S. Boye & W. J. Valentine & H. Sapin - 1197-1209 Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial
by Jose Antonio Robles-Zurita & Andrew Briggs & Dikshyanta Rana & Zahidul Quayyum & Keith G. Oldroyd & Uwe Zeymer & Steffen Desch & Suzanne Waha-Thiele & Holger Thiele - 1211-1221 Cost and effects of integrated care: a systematic literature review and meta-analysis
by Stephen Rocks & Daniela Berntson & Alejandro Gil-Salmerón & Mudathira Kadu & Nieves Ehrenberg & Viktoria Stein & Apostolos Tsiachristas - 1223-1233 The role of income disparities on survival in metastatic clear cell renal cell carcinoma in the targeted therapy era
by Yawen Zheng & Yilun Sun & Hongyan Yang & Jie Liu & Ligang Xing & Yuping Sun - 1235-1244 Estimating the monetary value of health and capability well-being applying the well-being valuation approach
by Sebastian Himmler & Job Exel & Werner Brouwer - 1245-1257 Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines
by Matthew Kennedy-Martin & Bernhard Slaap & Michael Herdman & Mandy Reenen & Tessa Kennedy-Martin & Wolfgang Greiner & Jan Busschbach & Kristina S. Boye - 1259-1272 The impact of the great economic crisis on mental health care in Italy
by Yuxi Wang & Giovanni Fattore
September 2020, Volume 21, Issue 7
- 977-982 Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19
by Sebastian Neumann-Böhme & Nirosha Elsem Varghese & Iryna Sabat & Pedro Pita Barros & Werner Brouwer & Job Exel & Jonas Schreyögg & Tom Stargardt - 983-992 Discrete choice experiments to generate utility values for multi-attribute utility instruments: a systematic review of methods
by Mina Bahrampour & Joshua Byrnes & Richard Norman & Paul A. Scuffham & Martin Downes - 993-1002 Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening
by Rebecca L. Thomas & Thomas G. Winfield & Matthew Prettyjohns & Frank D. Dunstan & Wai-Yee Cheung & Philippa M. Anderson & Rajesh Peter & Stephen D. Luzio & David R. Owens - 1003-1013 Patterns of care and cost profiles of women with breast cancer in Italy: EPICOST study based on real world data
by Silvia Francisci & Stefano Guzzinati & Giulia Capodaglio & Daniela Pierannunzio & Sandra Mallone & Andrea Tavilla & Tania Lopez & Susanna Busco & Walter Mazzucco & Catia Angiolini & Manuel Zorzi & Diego Serraino & Alessandro Barchielli & Mario Fusco & Fabrizio Stracci & Fortunato Bianconi & Massimo Rugge & Silvia Iacovacci & Antonio Giampiero Russo & Rosanna Cusimano & Anna Gigli - 1015-1023 Quantifying the economic impact of caregiving for Duchenne muscular dystrophy (DMD) in Spain
by David Flores & María P. Ribate & Marisol Montolio & Feliciano J. Ramos & Manuel Gómez & Cristina B. García - 1025-1038 Impacts of air pollution on health: evidence from longitudinal cohort data of patients with cardiovascular diseases
by Clifford Afoakwah & Son Nghiem & Paul Scuffham & Quan Huynh & Tom Marwick & Joshua Byrnes - 1039-1048 Measuring intangible cost-of-morbidity due to substance dependence: implications of using alternative preference-based instruments
by Bruno Casal & Eva Rodríguez-Míguez & Berta Rivera - 1049-1057 Predictors of negotiated prices for new drugs in Germany
by Afschin Gandjour & Sofia Schüßler & Thomas Hammerschmidt & Charalabos-Markos Dintsios - 1059-1073 Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)
by Gabrielle Jongeneel & Marjolein J. E. Greuter & Felice N. Erning & Miriam Koopman & Jan P. Medema & Raju Kandimalla & Ajay Goel & Luis Bujanda & Gerrit A. Meijer & Remond J. A. Fijneman & Martijn G. H. Oijen & Jan Ijzermans & Cornelis J. A. Punt & Geraldine R. Vink & Veerle M. H. Coupé - 1075-1089 The excess economic burden of mental disorders: findings from a cross-sectional prevalence survey in Austria
by Agata Łaszewska & Johannes Wancata & Rebecca Jahn & Judit Simon - 1091-1103 An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values
by Koonal K. Shah & Juan Manuel Ramos-Goñi & Simone Kreimeier & Nancy J. Devlin - 1105-1116 Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan’s health care system
by Tsung-Ying Lee & Hsuan-Ying Chen & Tsai-Yun Chen & Sin-Syue Li & Wei-Tse Fang & Yao-Chun Wen & Yu-Wen Lo & Huang-Tz Ou
August 2020, Volume 21, Issue 6
- 817-823 Historical evidence for economic effects of COVID-19
by Rahmiye Figen Ceylan & Burhan Ozkan & Esra Mulazimogullari - 825-844 Cost-effectiveness of a non-pharmacological treatment vs. “care as usual” in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial
by Kathrin Steinbeisser & Larissa Schwarzkopf & Elmar Graessel & Hildegard Seidl - 845-853 A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics
by Joost W. Geenen & Svetlana V. Belitser & Rick A. Vreman & Martijn Bloois & Olaf H. Klungel & Cornelis Boersma & Anke M. Hövels - 855-867 The pass-through of alcohol excise taxes to prices in OECD countries
by Ce Shang & Anh Ngo & Frank J. Chaloupka - 869-879 Health-related quality of life in elderly people with hypertension and the estimation of minimally important difference using EQ-5D-5L in Hong Kong SAR, China
by Eliza Lai Yi Wong & Richard Huan Xu & Annie Wai Ling Cheung - 881-893 Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer
by C. Thoren & C. Balg & J. Gibbert & S. Mostardt & M. Ripoll & D. Schierbaum & S. Schiller & A. Schwalm - 895-901 A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland
by Felicity Lamrock & Laura McCullagh & Lesley Tilson & Michael Barry - 903-915 Does linear equating improve prediction in mapping? Crosswalking MacNew onto EQ-5D-5L value sets
by Admassu N. Lamu - 917-930 How expensive are post-traumatic stress disorders? Estimating incremental health care and economic costs on anonymised claims data
by Tim Bothe & Josephine Jacob & Christoph Kröger & Jochen Walker - 931-943 Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
by Lotte Westerink & Jelmer L. J. Nicolai & Carl Samuelsen & Hans J. M. Smit & Pieter E. Postmus & Ingolf Griebsch & Maarten J. Postma - 945-962 The effect of time to death on health care expenditures: taking into account the endogeneity and right censoring of time to death
by Christophe Kolodziejczyk - 963-975 Lifetime cost of unilateral cochlear implants in adults: a Monte Carlo simulation
by Christin Thum & Thomas Lenarz & Anke Lesinski-Schiedat & Steffen Fleßa
July 2020, Volume 21, Issue 5
- 665-668 Modelling Covid-19 under uncertainty: what can we expect?
by Meimei Wang & Steffen Flessa - 669-687 Corruption in public health and its effects on the economic growth of Brazilian municipalities
by Eduarda Machoski & Jevuks Matheus Araujo - 689-702 Are quality-adjusted medical prices declining for chronic disease? Evidence from diabetes care in four health systems
by Karen Eggleston & Brian K. Chen & Chih-Hung Chen & Ying Isabel Chen & Talitha Feenstra & Toshiaki Iizuka & Janet Tin Kei Lam & Gabriel M. Leung & Jui-fen Rachel Lu & Beatriz Rodriguez-Sanchez & Jeroen N. Struijs & Jianchao Quan & Joseph P. Newhouse - 703-716 Improving access to services for psychotic patients: does implementing a waiting time target make a difference
by Anika Kreutzberg & Rowena Jacobs - 717-728 Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials
by Bernhard Michalowsky & Wolfgang Hoffmann & Kevin Kennedy & Feng Xie - 729-743 Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications
by John Yfantopoulos & Athanasios Chantzaras - 745-750 The Amsterdam Wrist Rules: how much money can they save?
by Marjolein A. M. Mulders & Monique M. J. Walenkamp & Nico L. Sosef & Frank Ouwehand & Romuald van Velde & J. Carel Goslings & Niels W. L. Schep - 751-761 How does the integration of collaborative care elements in a gatekeeping system affect the costs for mental health care in Germany?
by Alexander Engels & Katrin Christiane Reber & Julia Luise Magaard & Martin Härter & Sabine Hawighorst-Knapstein & Ariane Chaudhuri & Christian Brettschneider & Hans-Helmut König - 763-773 Willingness to pay for an early warning system for infectious diseases
by Sebastian Himmler & Job Exel & Meg Perry-Duxbury & Werner Brouwer - 775-785 Incidence and costs of hospitalized adult influenza patients in The Netherlands: a retrospective observational study
by Sierk D. Marbus & Valentijn A. Schweitzer & Geert H. Groeneveld & Jan J. Oosterheert & Peter M. Schneeberger & Wim Hoek & Jaap T. Dissel & Arianne B. Gageldonk-Lafeber & Marie-Josée Mangen - 787-800 Transforming discrete choice experiment latent scale values for EQ-5D-3L using the visual analogue scale
by Edward J. D. Webb & John O’Dwyer & David Meads & Paul Kind & Penny Wright - 801-811 Healthcare expenditure and carbon footprint in the USA: evidence from hidden cointegration approach
by Murat Gündüz - 813-814 Reply to the comment on “Trends in rates of orthopedic surgery in Germany: the good, the bad, the ugly.”
by Natalie Baier & Lisa-Marie Sax & Leonie Sundmacher - 815-815 Correction to: Defensive medicine in Europe: a ‘full circle’?
by Livio Garattini & Anna Padula
June 2020, Volume 21, Issue 4
- 477-482 Defensive medicine in Europe: a ‘full circle’?
by Livio Garattini & Anna Padula - 483-500 Low risk, high reward? Repeated competitive biddings with multiple winners in health care
by Visa Pitkänen & Signe Jauhiainen & Ismo Linnosmaa - 501-511 A vision ‘bolt-on’ increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery
by Mihir Gandhi & Marcus Ang & Kelvin Teo & Chee Wai Wong & Yvonne Chung-Hsi Wei & Rachel Lee-Yin Tan & Mathieu F. Janssen & Nan Luo - 513-528 Incorporating self-reported health measures in risk equalization through constrained regression
by A. A. Withagen-Koster & R. C. Kleef & F. Eijkenaar - 529-542 A general framework for classifying costing methods for economic evaluation of health care
by Zuzana Špacírová & David Epstein & Leticia García-Mochón & Joan Rovira & Antonio Olry de Labry Lima & Jaime Espín - 543-555 Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France
by Gabriel Tremblay & Clemence Cariou & Christian Recher & Mike Dolph & Patricia Brandt & Anne-Sandrine Blanc & Anna Forsythe - 557-572 Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients
by Simone A. Huygens & Isaac Corro Ramos & Carlijn V. C. Bouten & Jolanda Kluin & Shih Ting Chiu & Gary L. Grunkemeier & Johanna J. M. Takkenberg & Maureen P. M. H. Rutten-van Mölken - 573-605 Biases in health expectancies due to educational differences in survey participation of older Europeans: It’s worth weighting for
by Sonja Spitzer - 607-619 Patients with coronary artery disease after acute myocardial infarction: effects of continuous enrollment in a structured Disease Management Program on adherence to guideline-recommended medication, health care expenditures, and survival
by Florian Kirsch & Christian Becker & Anja Schramm & Werner Maier & Reiner Leidl - 621-634 Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries
by B. Corbacho & M. Drummond & R. Santos & E. Jones & J. M. Borràs & J. Mestre-Ferrandiz & J. Espín & N. Henry & A. Prat - 635-648 Cost of poor health to the labour market returns to education in Australia: another pathway for socio-economic inequality
by Tinh Doan & Lyndall Strazdins & Liana Leach - 649-662 Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population
by Carmen Selva-Sevilla & Paula Ferrara & Manuel Gerónimo-Pardo - 663-664 Trends in rates of orthopedic surgery in Germany: the good, the bad, and the ugly
by Afschin Gandjour
April 2020, Volume 21, Issue 3
- 311-320 Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment
by Elisabete Gonçalves - 321-334 Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach
by Paal Joranger & Arild Nesbakken & Halfdan Sorbye & Geir Hoff & Arne Oshaug & Eline Aas - 335-349 Cost-effectiveness analysis of the Neuropad device as a screening tool for early diabetic peripheral neuropathy
by B. Rodríguez-Sánchez & L. M. Peña-Longobardo & A. J. Sinclair - 351-362 Unfolding the relationship between mortality, economic fluctuations, and health in Italy
by Maddalena Cavicchioli & Barbara Pistoresi - 363-379 The societal monetary value of a QALY associated with EQ-5D-3L health gains
by Laura Vallejo-Torres & Borja García-Lorenzo & Oliver Rivero-Arias & José Luis Pinto-Prades - 381-396 Non-compensatory aggregation method to measure social and material deprivation in an urban area: relationship with premature mortality
by Carolina Bruzzi & Enrico Ivaldi & Stefano Landi - 397-407 Health state utilities associated with treatment for transfusion-dependent β-thalassemia
by Louis S. Matza & L. Clark Paramore & Katie D. Stewart & Hayley Karn & Minesh Jobanputra & Andrew C. Dietz - 409-423 Austerity, healthcare provision, and health outcomes in Spain
by Cristina Borra & Jerònia Pons-Pons & Margarita Vilar-Rodríguez - 425-436 Once bitten, twice shy? Lessons learned from an experiment to liberalize price regulations for dental care
by Anna-Lena Trescher & Stefan Listl & Onno Galien & Frank Gabel & Olivier Kalmus - 437-449 Cost-effectiveness and budget impact of the microprocessor-controlled knee C-Leg in transfemoral amputees with and without diabetes mellitus
by Alexander Kuhlmann & Henning Krüger & Susanne Seidinger & Andreas Hahn - 451-464 Healthcare costs associated with breast cancer in Germany: a claims data analysis
by Kristine Kreis & Marika Plöthner & Torben Schmidt & Richard Seufert & Katharina Schreeb & Veronika Jahndel & Sylke Maas & Alexander Kuhlmann & Jan Zeidler & Anja Schramm - 465-473 A comparison of individual and collective decision making for standard gamble and time trade-off
by Arthur E. Attema & Han Bleichrodt & Olivier l’Haridon & Stefan A. Lipman - 475-475 Correction to: Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma
by Laura Amanda Vallejo-Aparicio & Jesús Molina & Iñigo Ojanguren & Ana Viejo Casas & Alicia Huerta & Henrik Svedsater
March 2020, Volume 21, Issue 2
- 165-170 Defensive medicine in Europe: a ‘full circle’?
by Livio Garattini & Anna Padula - 171-180 Measuring horizontal inequity in healthcare utilisation: a review of methodological developments and debates
by Mohammad Habibullah Pulok & Kees Gool & Mohammad Hajizadeh & Sara Allin & Jane Hall - 181-194 The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature
by Anees ur Rehman & Mohamed Azmi Ahmad Hassali & Sohail Ayaz Muhammad & Sabariah Noor Harun & Shahid Shah & Sameen Abbas - 195-207 Corruption and health outcomes within an economic and cultural framework
by Monica Violeta Achim & Viorela Ligia Văidean & Sorin Nicolae Borlea - 209-218 Why are there long waits at English emergency departments?
by James Gaughan & Panagiotis Kasteridis & Anne Mason & Andrew Street - 219-233 Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
by M. Campioni & I. Agirrezabal & R. Hajek & J. Minarik & L. Pour & I. Spicka & S. Gonzalez-McQuire & P. Jandova & V. Maisnar - 235-249 The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France
by Gérard de Pouvourville & Patrick Blin & Pierre Karam - 251-259 The company you keep: health behavior among work peers
by Gerald J. Pruckner & Thomas Schober & Katrin Zocher - 261-274 The impact of prescription drug co-payments for publicly insured families
by Gretta Mohan & Anne Nolan - 275-285 How averse are the UK general public to inequalities in health between socioeconomic groups? A systematic review
by Simon McNamara & John Holmes & Abigail K. Stevely & Aki Tsuchiya - 287-296 Cognitive ability and teen smoking
by Hendrik Jürges & Sophie-Charlotte Meyer - 297-309 Economic evaluation of meningococcal vaccines: considerations for the future
by Hannah Christensen & Hareth Al-Janabi & Pierre Levy & Maarten J. Postma & David E. Bloom & Paolo Landa & Oliver Damm & David M. Salisbury & Javier Diez-Domingo & Adrian K. Towse & Paula K. Lorgelly & Koonal K. Shah & Karla Hernandez-Villafuerte & Vinny Smith & Linda Glennie & Claire Wright & Laura York & Raymond Farkouh
February 2020, Volume 21, Issue 1
- 1-5 HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?
by Livio Garattini & Anna Padula - 7-17 Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma
by Laura Amanda Vallejo-Aparicio & Jesús Molina & Iñigo Ojanguren & Ana Viejo Casas & Alicia Huerta & Henrik Svedsater - 19-36 The income gradient and child mental health in Australia: does it vary by assessors?
by Rasheda Khanam & Son Nghiem & Maisha Rahman - 37-44 Speeding up the clinical pathways by accessing emergency departments
by Rosella Levaggi & Marcello Montefiori & Luca Persico